Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 653-660

  Emery, Paul ^a,b   Gallo, Gaia ^c   Boyd, Helen ^d   Morgan, Christopher L ^e   Currie, Craig J ^f   Poole, Christopher D ^e,f   Nab, Henk W ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e Pharmatelligence ^*  (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Disease modifying anti rheumatic drugs; Etanercept; Rheumatoid arthritis; Serious infection

Indexed keywords

ANTIBIOTIC AGENT; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMMUNICABLE DISEASES; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; LINEAR MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907577610     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
2. LIPSKY PE, van der HEIJDE DM, st CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti- Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
3. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: twoyear radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
4. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
5. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
6. KLARESKOG L, van der HEIJDE D, de JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
7. MAINI R, st CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
8. ASKLING J, FORED CM, GEBOREK P et al.: Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12.
9. ZINK A, LISTING J, KARY S et al.: Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274-9.
10. WATSON K, SYMMONS D, GRIFFITHS I, SILMAN A: The British Society for Rheumatology biologics register. Ann Rheum Dis 2005; 64 Suppl 4: iv42-3.
11. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
12. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
13. LEOMBRUNO JP, EINARSON TR, KEYSTONE EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.
14. GALLOWAY JB, HYRICH KL, MERCER LK et al.: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011; 50: 124-31.
15. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
16. ASKLING J, FORED CM, BRANDT L et al.: Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44.
17. AU K, REED G, CURTIS JR et al.: High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785-91.
18. CHARLSON ME, POMPEI P, ALES KL, MACKENZIE CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
19. CURTIS JR, PATKAR N, XIE A et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33.
20. ZHANG N, WILKINSON S, RIAZ M, OSTOR AJ, NISAR MK: Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol 2012; 30: 962-71.
21. van DARTEL SA, FRANSEN J, KIEVIT W et al.: Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72: 895-900.
22. KLARESKOG L, GAUBITZ M, RODRIGUEZVALVERDE V, MALAISE M, DOUGADOS M, WAJDULA J: Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 238-47.
23. STRANGFELD A, EVESLAGE M, SCHNEIDER M et al.: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
24. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE: Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130). [Online]. 2007. http://www.nice. org.uk/ta130. Accessed July 2013.
25. FAVALLI EG, DESIATI F, ATZENI F et al.: Serious infections during anti-TNF-alpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 266-73.
26. DIXON WG, SYMMONS DP, LUNT M, WATSON KD, HYRICH KL, SILMAN AJ: Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904.